Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer Fausto PetrelliSandro Barni Review 01 November 2013 Pages: 227 - 235
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes Aleix PratOlga KarginovaCharles M. Perou Preclinical Study Open access 27 October 2013 Pages: 237 - 255
Genomic profiling of histological special types of breast cancer Hugo M. HorlingsBritta WeigeltJorge S. Reis-Filho Preclinical study 27 October 2013 Pages: 257 - 269
Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling Reginald M. GorczynskiZhiqi ChenKai Yu Preclinical study Open access 29 October 2013 Pages: 271 - 282
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue Myriam VilascoLaudine CommunalBRACAPS Preclinical Study 29 October 2013 Pages: 283 - 296
RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial–mesenchymal transition Chonggao YinHongli LiWeiyi Chen Preclinical Study 01 November 2013 Pages: 297 - 309
Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers Julia Y. S. TsangYing Kin KwokGary M. Tse Preclinical study 02 November 2013 Pages: 311 - 322
The prognostic value of apoptotic and proliferative markers in breast cancer Charla C. EngelsFrancesca RubertaPeter J. K. Kuppen Preclinical Study 06 November 2013 Pages: 323 - 339
Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells Molly A. TaylorGangarao DavuluriKhalid Sossey-Alaoui Preclinical study 07 November 2013 Pages: 341 - 353
Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients Esther M. de KruijfCharla C. EngelsPeter J. K. Kuppen Preclinical study 07 November 2013 Pages: 355 - 364
Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns Sabrina A. BardowellJoel ParkerTheresa Swift-Scanlan Preclinical Study Open access 10 November 2013 Pages: 365 - 380
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients John W. Smith IISvetislava VukeljaJoyce O’Shaughnessy Clinical Trial 29 October 2013 Pages: 381 - 388
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk Shaveta VinayakErich J. SchwartzAllison W. Kurian Clinical Trial 29 October 2013 Pages: 389 - 398
Ultrasonic dissection system technology in breast cancer: a case–control study in a large cohort of patients requiring axillary dissection F. LumachiS. M. M. BassoG. B. Chiara Clinical trial 02 November 2013 Pages: 399 - 404
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases Nancy U. LinRachel A. FreedmanEric P. Winer Clinical trial 07 November 2013 Pages: 405 - 414
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 Kalliopi P. SiziopikouStewart J. AndersonNorman Wolmark Clinical trial 08 November 2013 Pages: 415 - 421
Barriers to physical activity and healthy eating in young breast cancer survivors: modifiable risk factors and associations with body mass index Emily E. VenturaPatricia A. GanzCatherine M. Crespi Epidemiology 01 November 2013 Pages: 423 - 433
Aromatase inhibitor therapy and hair loss among breast cancer survivors Lisa GallicchioCarla CalhounKathy J. Helzlsouer Epidemiology 07 November 2013 Pages: 435 - 443
Is there a role for routine screening MRI in women with LCIS? Tari A. KingShirin MuhsenMonica Morrow Brief Report 19 October 2013 Pages: 445 - 453
Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93 Olivia PaganiShari GelberEdda Simoncini Brief Report 07 November 2013 Pages: 455 - 459
Closing an on-going clinical trial: when is it betrayal of participants? Cynthia ChauhanMary Lou Smith Letter to the Editor Open access 26 October 2013 Pages: 461 - 462
Margin negative, breast conserving resection: adequate for benign phyllodes tumors, but inadequate therapy for borderline and malignant phyllodes tumors Richard J. Barth Jr. Invited Commentary 01 November 2013 Pages: 463 - 464
